FTC sues three largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged anticompetitive practices that boosted profits while “artificially” inflating the list price of insulin.
The agency’s action targeted CVS Caremark Rx, Cigna’s Express Scripts and UnitedHealth’s OptumRx. The three companies combined administer about 80 percent of all prescriptions in the United States.
The FTC accused the companies of creating a “perverse” drug rebate system that prioritizes insulin from manufacturers sold at a higher list price even when cheaper versions are available.
The system allowed the PBMs and their affiliated group purchasing organizations, which broker drug purchases for hospitals and other providers, to “line their pockets” with bigger rebates while patients pay higher out-of-pocket costs, the complaint alleged.
The FTC in a statement said one PBM Vice President acknowledged the strategy allowed the Big Three to continue to “drink down the tasty … rebates.”
“Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed,” Rahul Rao, Deputy Director of the FTC’s Bureau of Competition said in a statement.
“Caremark, ESI, and Optum—as medication gatekeepers—have extracted millions of dollars off the backs of patients who need life-saving medications,” Rao said.
The lawsuit, which hasn’t yet been made public, represents an escalation of the Biden administration’s scrutiny of the business practices of PBMs, seeking to shine light on the opaque intermediaries at the center of the pharmaceutical distribution system.
The companies forcefully pushed back.
“This action continues a troubling pattern from the FTC of unsubstantiated and ideologically-driven attacks on pharmacy benefit managers,” said Andrea Nelson, chief legal officer of the Cigna Group.
Cigna’s Express Scripts sued the FTC on Tuesday over an interim report issued in July on PBMs, demanded the report be retracted because it is “filled with false and misleading claims” about the PBM industry.
A spokeswoman for Optum Rx said the FTC’s “baseless action demonstrates a profound misunderstanding of how drug pricing works.”
A CVS Caremark spokesman said it is “proud of the work we have done to make insulin more affordable for all Americans with diabetes. To suggest anything else, as the FTC did today, is simply wrong. We stand by our record of protecting American businesses, unions, and patients from rising prescription drug prices.
PBMs negotiate the terms and conditions for access to prescription drugs for hundreds of millions of Americans. They are responsible for negotiating prices with drug companies, paying pharmacies and determining which drugs patients can access and how much they cost.
As the industry has grown more consolidated, critics say PBMs have exerted greater control over patients’ access to medicine. PBMs are vertically integrated, serving as health plans and pharmacists. The largest PBMs are owned by insurers, which own specialty, mail order or retail pharmacies.
Drug companies and PBMs each blame the other for rising drug costs. Manufacturers say they need to raise list prices because of high PBM rebates, but the intermediaries argue that those rebates are passed on to health plan sponsors.
But the FTC said that PBMs aren’t necessarily the only ones to blame for high insulin prices. The Bureau of Competition “remains deeply troubled by the role drug manufacturers like Eli Lilly, Novo Nordisk, and Sanofi play in driving up list prices of life-saving medications like insulin,” FTC said.
The agency said it “may recommend suing drug manufacturers” in the future.
Date: |
Topics
-
CNBC - Business
FTC sues drug middlemen for allegedly inflating insulin prices
The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts.4 hours ago -
The Wall Street Journal - Business
FTC Accuses Drug Middlemen of Inflating Insulin Prices
The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms of inflating the price of insulin.8 hours ago -
NBC News - Top stories
Federal Trade Commission accuses three drug middlemen of inflating insulin prices
The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.2 hours ago -
The New York Times - Health
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more.8 hours ago -
MarketWatch - Business
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also ‘on notice’
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.5 hours ago -
CBS News - Top stories
Drug middlemen illegally drive up the cost of insulin, FTC says
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.3 hours ago -
Financial Times - Business
US drug ‘gatekeepers’ face FTC antitrust lawsuit over insulin prices
Complaint alleges pharmacy benefit managers owned by CVS, Cigna and UnitedHealth are keeping prices high7 hours ago -
ABC News - Health
High insulin prices spur a federal lawsuit against three pharmacy benefit managers
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients3 hours ago -
NBC News - Top stories
Cards Against Humanity sues Elon Musk's SpaceX for allegedly trespassing on Texas land
The games company Cards Against Humanity says that Elon Musk's SpaceX has been storing construction materials on its land without permission.5 hours ago
More from The Hill
-
The Hill - Politics
Harris tells Wisconsin rally: ‘Let’s not pay too much attention to the polls’
Vice President Harris on Friday night told rallygoers in Wisconsin not to pay too much attention to the polls, which paint the presidential race as largely neck-and-neck against former President ...25 minutes ago -
The Hill - Politics
GOP senator suggests Mark Robinson should take legal action or leave the race
Republican Sen. Thom Tillis (R-N.C.) suggested that North Carolina’s GOP gubernatorial candidate Mark Robinson should take legal action against the media or exit the race. “If the reporting on ...42 minutes ago -
The Hill - Politics
Harris adviser says quip on shooting intruder was 'a joke'
Harris campaign adviser Keisha Lance Bottoms said the vice president’s comment to Oprah Winfrey Thursday night that she would shoot someone who broke into her house was a “joke.” “It was a joke, ...1 hour ago -
The Hill - Politics
US anticipates announcement to cut back troops in Iraq next week
A long-expected deal to reduce U.S. troop presence in Iraq will likely be announced next week, two administration officials said Friday. The agreement with Iraq, which would reduce American troops ...1 hour ago - Iraq -
The Hill - Politics
At-home flu vaccines get FDA approval
Presented by Plan B One Step — For the first time, adults will be able to administer their own flu vaccines after the FDA approved a nasal spray to be administered without a health care provider ...2 hours ago - FDA